NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions

UveitisMacular EdemaUveitis, PosteriorUveitis, AnteriorPanuveitisUveitis, Intermediate

Interventions

DRUG

4 mg CLS-TA

40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)

DRUG

0.8 mg CLS-TA

8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)

Trial Locations (11)

New York

Winston-Salem

Atlanta

Miami

Cleveland

Fargo

Chicago

Omaha

Dallas

Boston

Waltham